Howard H. Bailey, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Howard Bailey is a medical oncologist who specializes in gynecologic oncology and cancer prevention at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center. He is Associate Director for Clinical Programs of the UW Carbone Cancer Center and Associate Director of the University of Wisconsin’s General Clinical Research Center, a center within UW Hospital and Clinics, devoted solely to clinical research.
Specialties
UW Health Clinics
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Internal Medicine
Medical Oncology |
| Fellowship |
UW Comprehensive Cancer Center
|
| Residency |
Southwestern Michigan Area Health Education Center, Kalamazoo
|
| Internship |
Southwestern Michigan Area Health Education Center, Kalamazoo
|
| Medical School |
University of North Dakota, 1985
|
Awards/Honors
Programs & Conditions
| Research |
Dr. Bailey is involved in the research of new clinical agents for the prevention and treatment of cancer. He leads the Etiology and Chemoprevention Program of the UW Carbone Cancer Center - which examines the causes of cancer and then translates this knowledge to develop and evaluate drugs, vitamins, or other agents to try to reduce the risk of or delay the development of cancer. He is the principal investigator of the Chemoprevention Consortium - a consortium of five national institutions to conduct multiple Phase I and II clinical trials for chemopreventive agents. |
PubMed Articles
-
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G .
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jan 17;
[PubMed ID: 23335089]
-
Rocque GB Barnett AE Illig LC Eickhoff JC Bailey HH Campbell TC Stewart JA Cleary JF .
Inpatient Hospitalization of Oncology Patients: Are We Missing an Opportunity for End-of-Life Care? J Oncol Pract. 2013 Jan;9(1):51-4
[PubMed ID: 23633971]
-
Kreul SM Havighurst T Kim K Mendonça EA Wood GS Snow S Borich A Verma A Bailey HH .
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74
[PubMed ID: 23060038]
-
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
-
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS .
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
-
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS .
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 May 17;
[PubMed ID: 21585283]
-
Traynor AM Thomas JP Ramanathan RK Mody TD Alberti D Wilding G Bailey HH .
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr;29(2):316-22
[PubMed ID: 19997959]
-
Kolesar JM Hoel R Pomplun M Havighurst T Stublaski J Wollmer B Krontiras H Brouillette W Muccio D Kim K Grubbs CJ Bailey HE .
A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70
[PubMed ID: 21149332]
-
Attia S Dezube BJ Torrealba JR Sosman JM McHaffie DR Pfau PR Bailey HH Kozak KR .
AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol. 2010 Jun 1;28(16):e250-1
[PubMed ID: 20439636]
-
Weiss JM Attia S Bailey HH Weber S Hu J Reichelderfer M Gopal DV .
Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy. J Clin Oncol. 2010 May 20;28(15):e233-5
[PubMed ID: 20368563]
-
Bailey HH Kim K Verma AK Sielaff K Larson PO Snow S Lenaghan T Viner JL Douglas J Dreckschmidt NE Hamielec M Pomplun M Sharata HH Puchalsky D Berg ER Havighurst TC Carbone PP .
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila). 2010 Jan;3(1):35-47
[PubMed ID: 20051371]
-
Bailey H Agger W Baumgardner D Burmester JK Cisler RA Evertsen J Glurich I Hartman D Yale SH DeMets D .
The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group. WMJ. 2009 Dec;108(9):453-8
[PubMed ID: 20131687]
-
Jensen ME Hartenbach E McElroy JA Faerber A Havighurst T Kim KM Bailey HH .
Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine. WMJ. 2009 Jul;108(4):203-5
[PubMed ID: 19753828]
-
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
-
Schelman W Morgan-Meadows S Bailey H Holen K Thomas JP Eickhoff J Brandon H Oliver K Alberti D Wilding G .
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep;62(4):727-33
[PubMed ID: 18172649]
-
Bailey HH Attia S Love RR Fass T Chappell R Tutsch K Harris L Jumonville A Hansen R Shapiro GR Stewart JA .
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57
[PubMed ID: 17885756]
-
Petrich A Kahl B Bailey H Kim K Turman N Juckett M .
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma. 2008 Jan;49(1):57-61
[PubMed ID: 18203012]
-
Bailey HH Alberti DB Thomas JP Mulkerin DL Binger KA Gottardis MM Martell RE Wilding G .
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res. 2007 Jun 15;13(12):3623-9
[PubMed ID: 17510207]
-
Kushner DM Connor JP Sanchez F Volk M Schink JC Bailey HH Harris LS Stewart SL Fine J Hartenbach EM .
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007 May;105(2):358-64
[PubMed ID: 17258800]
-
Bailey HH Mahoney MR Ettinger DS Maples WJ Fracasso PM Traynor AM Erlichman C Okuno SH .
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006 Nov 15;107(10):2462-7
[PubMed ID: 17058289]
-
Kahl BS Bailey HH Smith EP Turman N Smith J Werndli J Williams EC Longo WL Kim KM McGovern J Jumonville A .
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005;23(1):13-8
[PubMed ID: 15779863]
